The expression of PINX1, a possible telomerase inhibitor and a putative tumor suppressor, has not been studied in human cancers, including gastric cancer (GC). We examined expression of PINX1 by quantitative reverse transcription (RT)-PCR in 73 cases of GC, and 45 of these cases were further studied for loss of heterozygosity (LOH) by PCR with microsatellite marker D8S277. Reduced expression (tumor vs normal ratioo0.5) of PINX1 was detected in 50 (68.5%) of 73 cases of GC. GC tissues with reduced expression of PINX1 showed significantly higher telomerase activities as measured by telomeric repeat amplification protocol than those with normal expression of PINX1 (P ¼ 0.031). LOH of PINX1 locus was detected in 15 (33.3%) of 45 cases of GC and was correlated significantly with reduced expression of PINX1 (P ¼ 0.031). Expression of PINX1 in a GC cell line, MKN-74, was induced by treatment with trichostatin A (TSA) or nicotinamide (NAM). Chromatin immunoprecipitation assay of MKN-74 cells revealed that acetylation of histone H4 in the 5 0 untranslated region (UTR) of PINX1 was enhanced by treatment with TSA or NAM, whereas acetylation of histone H3 was not changed by TSA or NAM. In addition, TSA or NAM treatment led to inhibition of telomerase activity in MKN-74 cells. These results indicate that LOH of PINX1 locus and hypoacetylation of histone H4 in the 5 0 UTR of PINX1 are associated with reduced expression of PINX1 in GC.
Introduction
PinX1 is a Pin2/TRF1-binding protein that is a potent inhibitor of telomerase (Zhou and Lu, 2001 ). PinX1 binds human telomerase reverse transcriptase (hTERT) and inhibits its activity directly. A novel human liverrelated putative tumor suppressor gene (LPTS) has been cloned previously (Liao et al., 2000) . LPTS gene is transcribed into two transcripts. The longer transcript, which is referred to as LPTS-L, encodes a 328-aminoacid protein (Liao et al., 2002) that is highly homologous to PinX1 (Zhou and Lu, 2001 ). LPTS-L and PinX1 have different 3 0 -untranslated regions but encode the same protein, which is referred to as LPTS-L/PinX1 (Liao et al., 2003) . LPTS-L/PinX1 has strong telomerase inhibitory activity both in vivo and in vitro (Zhou and Lu, 2001; Liao et al., 2002) . A high percentage of tumor cells with characteristics of immortalization show high telomerase activity (Shay and Bacchetti, 1997; Cong et al., 2002) . We previously reported that telomerase activity is present in a majority of gastric cancer (GC) types (Tahara et al., 1995; Yasui et al., 1998 Yasui et al., , 1999 . Loss of heterozygosity (LOH) of LPTS-L/PINX1 locus, which maps to human chromosome 8p23, was identified in 34.5% of hepatocellular carcinoma cases (Park et al., 2002) . 8p23, but not specifically PINX1, is frequently deleted in various cancers, including carcinomas of the liver (Emi et al., 1992) , lung , colorectum , prostate (Macoska et al., 1995) , and breast (Yaremko et al., 1995) , in addition to GC (Yustein et al., 1999; Baffa et al., 2000) . However, the significance of the LPTS-L/PINX1 gene in human cancers including GC remains unclear.
A variety of genetic and epigenetic alterations are associated with GC Oue et al., 2004) . Several lines of evidence suggest that histone acetylation plays an important role in transcriptional regulation (Grunstein, 1997) . Histone hyperacetylation is thought to relax the chromatin structure and allow transcription factors to access promoters (Luger et al., 1997; Luger and Richmond, 1998) . We have reported that trichostatin A (TSA), a histone deacetylase (HDAC) inhibitor, induces expression of p21 Waf1 and HLTF in GC cell lines (Suzuki et al., 2000; Hamai et al., 2003) . HDACs are separated into three distinct classes on the basis of their homologies to yeast transcriptional repressors (North et al., 2003) . Class I and II deacetylases are homologs of the yeast Rpd3p and Hda1p proteins, respectively. Class III deacetylases are classified on the basis of homology to the yeast transcriptional repressor, Sir2, which is nicotinamide adenine dinucleotide (NAD)-dependent HDAC (Imai et al., 2000; Landry et al., 2000; Smith et al., 2000) . TSA inhibits class I and II deacetylases, whereas nicotinamide (NAM) inhibits hSir2 (Luo et al., 2001; Bitterman et al., 2002) .
In the present study, we examined expression and LOH of PINX1 locus in GC. We also examined the association between expression of PINX1 and acetylation of histones in the 5 0 untranslated region (UTR) of PINX1 in GC cell lines.
Results

Expression of PINX1 in GC
Levels of PINX1 expression in 73 cases of GC are shown in Figure 1a . PINX1 levels were significantly lower in GC tissues (0.34770.138) than in non-neoplastic mucosa (1.76670.758, Po0.0001, Wilcoxon signed rank test). Reduced expression of PINX1 (tumor vs normal ratio o0.5) was detected in 50 (68.5%) of 73 cases of GC. Reduced expression of PINX1 in GC tissues was not significantly associated with T grade (depth of tumor invasion), N grade (degree of lymph node metastasis), tumor stage, or histological type (Table 1) .
Correlation between expression of PINX1 and telomerase activity in GC
We examined the correlation between PINX1 expression and telomerase activity in 20 of 73 cases of GC. GC tissues with reduced expression of PINX1 showed significantly higher telomerase activities than those with normal expression of PINX1 (4.60872.596 vs 1.43871.018, P ¼ 0.031, Mann-Whitney U-test, Figure 1b ).
LOH analysis of PINX1 locus in GC
LOH analysis was performed for 45 of 73 cases of GC, and representative results are shown in Figure 2a . LOH of PINX1 locus was detected in 15 (33.3%) of 45 cases of GC. Of 15 cases with LOH of PINX1 locus, 14 (93.3%) showed reduced expression of PINX1 ( Figure 2b and Table 2 ). Reduced expression of PINX1 was significantly associated with LOH of PINX1 locus (P ¼ 0.031; Fisher's exact test). LOH of PINX1 locus was not significantly associated with T grade, N grade, tumor stage, or histological type.
PINX1 expression status in GC cell lines
Next, we performed experiments with eight GC cell lines to further analyse PINX1 expression status. Quantitative RT-PCR analysis revealed that the average level of PINX1 expression in eight GC cell lines (0.69170.226) was less than a half of that in non-neoplastic mucosa of 73 cases (1.76670.758) (Figure 3a) . In particular, PINX1 expression level in MKN-74 cells was obviously lower than that in the seven other GC cell lines. Methylation of CpG island is an alternative way of causing the gene silencing of diverse tumor suppressor genes. To evaluate the extent of the PINX1 methylation, bisulfite sequencing was carried out in three cell lines . The PINX1 CpG islands of these cell lines were found to be little methylated over the entire region analysed (Figure 3b and Table 3 ). To further examine if the reduced expression of PINX1 is related to genomic alteration of the gene, Southern blot was performed in eight GC cell lines. No obvious alteration of PINX1 was found in all cell lines (Figure 3c ). Expression of PINX1 was significantly lower in GC tissues than in corresponding non-neoplastic mucosae (Po0.0001, Wilcoxon signed rank test). The expression value was calculated as the mean of three independent quantitative RT-PCR experiments. The units are arbitrary, and we calculated the PINX1 mRNA expression level by standardization against 1 mg of total RNA from HSC-39 GC cells, which was taken as 1.0. (b) Correlation between telomerase activity and reduced expression of PINX1. Reduced (T/No0.5), not reduced (T/NX0.5). Telomerase activities were higher in GC tissues with reduced expression of PINX1 than in those with normal PINX1 levels (P ¼ 0.031, Mann-Whitney U-test). We examined the correlation between PINX1 expression levels and telomerase activity in 20 of 73 cases for which telomerase activities were reported (Yasui et al., 1998) PINX1 expression in gastric carcinoma T Kondo et al Alteration of telomerase activity in MKN-74 treated with TSA and NAM PinX1 binds to hTERT and inhibits its activity directly (Zhou and Lu, 2001 ). To observe the alteration of telomerase activity when PINX1 expression is changed, we performed telomeric repeat amplification protocol (TRAP) assay in MKN-74 cells treated with TSA and NAM. Telomerase activity was reduced to 65.6% with TSA, and to 10.2% with NAM ( Figure 5a ). Levels of hTERT expression were not significantly changed by treatment with TSA or NAM (Figure 5b ).
Discussion
The PINX1 gene appears to function as a tumor suppressor; however, the association between PINX1 and GC has not been studied. We report here reduced expression of PINX1 in 50 (68.5%) of 73 GC cases. In all, 15 (33.3%) of 45 cases had LOH of PINX1 locus, which was correlated significantly with reduced expression of PINX1, suggesting that LOH plays a major role in reduced expression of PINX1. We did not find any association between reduced expression of PINX1 and According to the Lauren criteria (Lauren, 1965) . d According to the criteria of the TNM Stage classification system (Sobin and Wittekind, 1997) Figure 2 LOH of PINX1 locus in GC specimens and association between LOH and PINX1 expression. (a) Representative fluorescent electropherograms for LOH. Tumor tissues (T), corresponding non-neoplastic mucosae (N). Lost alleles are indicated by arrows. (b) Distribution of PINX1 expression in 45 cases of GC. T/ N ratio, PINX1 mRNA expression levels in GC tissue relative to levels in corresponding non-neoplastic mucosa. T/No0.5-fold is defined as reduced expression of PINX1 PINX1 expression in gastric carcinoma T Kondo et al frequency of LOH and T grade, N grade, or tumor stage. This finding suggests that downregulation of PINX1 may be involved in tumor development but not in tumor progression. We also found that telomerase activity is higher in GC tissues with reduced expression of PINX1 than in those with normal levels of PINX1. Reduced expression of PINX1 appears to be involved in activation of telomerase. Since PINX1 is located in the subtelomeric region of human chromosome 8, LOH of the PINX1 locus may occur easily through telomere dysfunction and chromosome instability during initiation of human cancers (Chin et al., 1999; Artandi et al., 2000; DePinho, 2000; O'Sullivan et al., 2002; Meeker et al., 2002; Van Heek et al., 2002) . Recently, we reported that inhibition of Pot1, a single-stranded telomeric DNA-binding protein, induces telomere dysfunction and that expression of POT1 is reduced in early-stage GC (Kondo et al., 2004) . Although hTERT, the catalytic subunit of telomerase, is essential for activation of telomerase, it is possible that downregulation of PINX1, due to LOH, contributes to activation of telomerase at an early stage of stomach carcinogenesis. In fact, we previously observed that telomerase is activated in precancerous conditions such as intestinal metaplasia and adenoma of the stomach (Tahara et al., 1995; Kuniyasu et al., 1997; Yasui et al., 1999) . Activation of telomerase is essential for cell immortality, and it may be a critical step in the development of cancers (Tahara et al., 1995) . PinX1 may inhibit telomerase activation in normal somatic cells.
We observed reduced expression of PINX1 in 19 (63.3%) of 30 cases of GC that did not have LOH of PINX1 locus. We hypothesized that DNA methylation , 1997; Jones and Baylin, 2002) . We have also reported DNA methylation of tumor suppressor genes in GC (Oue et al., 2001 (Oue et al., , 2002 Hamai et al., 2003; Oshimo et al., 2004 Our results also indicated that PINX1 acetylation may be controlled through two pathways of histone deacetylation. The first pathway may involve class I and/or II HDACs. The second pathway is inhibited by NAM, which suggests the involvement of the NADdependent TSA-resistant Sir2 deacetylase, which is a class III HDAC. Deacetylation by Sir2 occurs selectively at Lys 16 of histone H4 in yeast (Imai et al., 2000) . Therefore, we believe that acetylation of histone H4 in the 5 0 UTR of PINX1 was induced selectively by NAM in the present study.
Moreover, we revealed that telomerase activity was inhibited with TSA and NAM in MKN-74 cells, although hTERT expression was not changed. Thus, PinX1 inhibits telomerase activity without change of hTERT expression. Our results also provide a possibility for cancer therapy with NAM.
In conclusion, our data show that LOH of the PINX1 locus and hypoacetylation of histone H4 in the 5 0 UTR of PINX1 are associated with reduced expression of PINX1 in GC. However, we cannot exclude the possibility that reduced expression of PINX1 is associated with mutation or other factors. Further studies may provide a better understanding of the physiological function of PINX1 and its role as a tumor suppressor in stomach carcinogenesis.
Materials and methods
Tissue samples
A total of 73 GC samples from 73 patients were studied. Tumors and corresponding non-neoplastic mucosae were removed surgically at Hiroshima University Hospital, frozen immediately in liquid nitrogen, and stored at À801C until use. We confirmed microscopically that the carcinoma tissue specimens consisted mainly (480%) of carcinoma tissue, and that the non-neoplastic mucosae did not show any invasion by carcinoma cells or show significant inflammatory involvement. Histologic classification and tumor staging were carried out according to the Lauren classification system (Lauren, 1965) and the TNM Stage Grouping (UICC 5th Edition, 1997) (Sobin and Wittekind, 1997) . Telomerase activities were determined previously in 20 of the 73 GC samples by TRAP analysis (Yasui et al., 1998) .
Cell lines and drug treatment
Eight cell lines derived from human GC were used. The TMK-1 cell line was established in our laboratory from a poorly differentiated adenocarcinoma (Ochiai et al., 1985) . Five GC cell lines of the MKN series (MKN-1, adenosquamous cell carcinoma; MKN-7, MKN-28, and MKN-74, well-differentiated adenocarcinomas; and MKN-45, poorly differentiated adenocarcinoma) were kindly provided by Dr T Suzuki. KATO-III and HSC-39 cell lines, which were established from signet ring cell carcinomas, were kindly provided by Dr M Sekiguchi and Dr K Yanagihara (Yanagihara et al., 1991) , respectively. All cell lines were routinely maintained in RPMI 1640 (Nissui Pharmaceutical Co., Ltd, Tokyo, Japan) containing 10% fetal bovine serum (FBS) (Bio-Whittaker, Walkersville, MD, USA) in a humidified atmosphere of 5% CO 2 and 95% air at 371C. MKN-28 and MKN-74 cells were treated with 300 nM TSA (Wako, Tokyo, Japan) for 24 h or with 5 mM NAM (Sigma, St Louis, MO, USA) for 6 h.
Quantitative RT-PCR
Total RNA was extracted from tissues and cell lines with the RNeasy Mini Kit (Qiagen, Valencia, CA, USA). Total RNA (1 mg) was converted to cDNA with the First-Strand cDNA Synthesis Kit (Amersham Pharmacia Biotech, Uppsala, Sweden). To analyse the expression of PINX1 gene in GC tissues specimens and GC cell lines, we performed real-time RT-PCR. PCRs were performed with the SYBR Green PCR Core Reagent kit (Applied Biosystems, Foster City, CA, USA). Real-time detection of the emission intensity of SYBR Green bound to double-stranded DNAs was performed with the ABI PRISM 7700 Sequence Detection System (Applied Biosystems). The PINX1 cDNA and the ACTB cDNA (internal control) were amplified separately. Relative gene expression was determined from the threshold cycle for the PINX1 gene and the ACTB gene. Reference samples (HSC-39) were included on each assay plate to verify plate-to-plate consistency. Plates were normalized to each other with these reference samples. PCR amplification was performed in 96-well optical trays with caps with a 25 ml final reaction mixture according to the manufacturer's instructions. Quantitative RT-PCRs were performed in triplicate for each sample and primer set, and the mean of the three experiments was used as the relative quantification value. We analysed PINX1 levels in 73 cases of GC by calculating the ratio of PINX1 mRNA expression levels between carcinoma tissue and the corresponding non-neoplastic mucosa (T/N ratio). We considered a T/No0.5-fold to indicate reduced expression of PINX1. PINX1 primer sequences were 5 0 -CAC TCC AGA GGA GAA CGA AAC C-3 0 (sense) and 5 0 -CAC CGG CTT GGC AAA GTA CT-3 0 (antisense). ACTB primer sequences were 5 0 -TCA CCG AGC GCG GCT-3 0 (sense) and 5 0 -TAA TGT CAC GCA CGA TTT CCC-3 0 (antisense). We used TaqMan PreDeveloped Assay Reagents Human TERT and TaqMan bactin Control Reagents (Applied Biosystems) in hTERT expression analysis.
Genomic DNA extraction and LOH analysis
To examine LOH of PINX1 locus, we extracted genomic DNAs from GC tissues with a genomic DNA purification kit (Promega, Madison, WI, USA). LOH at microsatellite marker D8S277 was evaluated by PCR of tumor and normal specimens, and microcapillary electrophoresis of PCR products was carried out in an ABI PRISM 310 Genetic Analyzer (Applied Biosystems). GeneScan software (Applied Biosystems) was used to quantify and interpret the raw data. Allelic loss was calculated according to a previously described formula (Liloglou et al., 2000 (Liloglou et al., , 2001 . Among 73 GC cases, we evaluated 45 cases for which genomic DNA was available.
Bisulfite genomic DNA sequencing
To examine the DNA methylation patterns, we treated genomic DNA with sodium bisulfite, as described previously (Hermann et al., 1996) . In brief, 2 mg of genomic DNA was denatured by treatment with NaOH and modified with 3 M sodium bisulfite for 16 h. DNA samples were purified with Wizard DNA purification resin (Promega), treated with NaOH, precipitated with ethanol, and resuspended in 25 ml PINX1 expression in gastric carcinoma T Kondo et al of water. Treated DNAs were stored at À201C until needed. Sodium bisulfite-treated genomic DNAs were amplified with PINX1 gene-specific primers (primer 1 and primer 2, Figure 3b ). Primer 1 sequences were 5 0 -TTT GAT TTT TTT GGA GTT TTT AGT-3 0 (sense) and 5 0 -GCG ACC CAA AAT AAT TCT AAA-3 0 (antisense). Primer 2 sequences were 5 0 -GGG TTT TTT GAT GGA GAT TTT A-3 0 (sense) and 5 0 -ACG TTC AAC CAA CAT AAA CAT ATC-3 0 (antisense). Conditions for the PCR were 1 cycle at 941C for 10 min; 34 cycles at 941C for 1 min, at 541C for 1 min, and at 721C for 1 min, and 1 cycle at 721C for 4 min. The PCR product was cloned into the TA vector pCR2.1 (Invitrogen, Carlsbad, CA, USA). A total of 10 subclones were confirmed by restriction analysis and sequenced using the M13 reverse primer (Invitrogen) with a Prism 310 DNA Sequencer (Perkin-Elmer Applied Biosystems).
ChIP assay
ChIP assay of GC cell lines was performed as described previously with modification (Ferreira et al., 2001) . In brief, chromatin proteins were crosslinked to DNA by addition of formaldehyde directly to the culture medium to a final concentration of 1%. After 10-min incubation at room temperature, the cells were washed and scraped off the dishes into ice-cold phosphate-buffered saline (PBS) containing protease inhibitors. Cells were pelleted and then resuspended in SDS lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris-HCl, pH 8.1, protease inhibitor) for 10 min on ice. The lysate was sonicated to reduce the mean DNA fragment size to 300-1000 bp. The sample was centrifuged to remove cell debris and diluted 10-fold in ChIP dilution buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris-HCl, pH 8.1, 167 mM NaCl, protease inhibitors). The chromatin solution was precleared with 40 ml of a mixture of salmon sperm DNAprotein A agarose slurry (Upstate Biotechnology, Lake Placid, NY, USA) to reduce nonspecific background. After precleaning, the solution was centrifuged, and the supernatant was collected. In all, 5 ml of either antiacetylated histone H3 or H4 antibody (Upstate Biotechnology) was added to the chromatin solution and incubated overnight at 41C with agitation. A no-antibody control was also performed for each ChIP assay. After the overnight incubation, immune complexes were collected by addition of 60 ml of salmon sperm DNA-protein A agarose slurry (Upstate Biotech) and incubated at 41C with agitation for 1 h. Beads were washed five times, and the bound immune complexes were eluted with buffer containing 1% SDS and 0.1 M NaHCO 3 . Crosslinks were reversed by addition of 5 M NaCl and incubation at 651C for 4 h. Samples were then treated with proteinase K for 1 h, and DNA was purified by phenol/chloroform extraction and ethanol precipitation. We performed PCR analysis of immunoprecipitated DNA using primers specific for the 5 0 region of the ACTB gene. Each PCR product (15 ml) was loaded onto 8% nondenaturing polyacrylamide gels, separated by electrophoresis, stained with ethidium bromide, and visualized under UV light to confirm that there was no genomic DNA contamination of the noantibody control. For quantitative PCR analysis of immunoprecipitated DNAs, we performed real-time PCR as described above.
PINX1 primer (5 0 region) sequences were 5 0 -CCT GAG TCC AGT GCC CTA CTT T-3 0 (sense) and 5 
Southern blot analysis
High molecular weight genomic DNA was extracted with a DNA Extraction Kit (Stratagene Cloning System, La Jolla, CA, USA). Tissue DNA was digested with MspI, electrophoresed on 0.6% agarose gels, and blotted onto nitrocellulose filters. The filters were hybridized with the full-length cDNA PINX1 probe and then autoradiographed.
TRAP assay
TRAP assay was carried out with a TRAPEZE Telomerase Detection Kit (Intergen Company, Oxford, UK). Intensity of the TRAP product bands and of the internal control bands was determined with the use of NIH Image.
Statistical analysis
Statistical significance was assessed by Wilcoxon signed rank test, Mann-Whitney U-test, or Fisher's exact test. StatView 5.0 Macintosh software was used. The P-values of less than 0.05 were considered statistically significant.
